Hospital
Scripps Health
Scripps Health was paid $11.95M by Medicaid between Jan 2018 and Nov 2024, across 136 billing codes. Its largest line is 99499, — 19% of everything it billed.
33Billing provider infoSCRIPPS HEALTH
ENCINITAS, CA 92024
ENCINITAS, CA 92024
33aNPI1700829199assigned 06/14/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.95M
24GClaims316,611
24DCodes billed136
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#163 of 410
Median peer was paid$6.90M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 66,798 | $1.81M | |
| 2019 | 53,329 | $1.64M | |
| 2020 | 33,039 | $1.03M | |
| 2021 | 41,738 | $1.72M | |
| 2022 | 49,669 | $2.26M | |
| 2023 | 48,625 | $2.54M | |
| 2024incomplete | 23,413 | $955K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99499 | 19% | 9,489 | 7,505 | $2.31M | |
| 0450 | Emergency room services | 15% | 24,762 | 21,966 | $1.79M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.5% | 15,118 | 14,773 | $1.13M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.3% | 8,857 | 8,054 | $629K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.7% | 2,045 | 1,875 | $565K |
| 80053 | Comprehensive metabolic panel | 4.1% | 30,599 | 28,171 | $487K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.3% | 12,930 | 11,914 | $391K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.0% | 2,174 | 2,148 | $357K |
| 0762 | 3.0% | 264 | 253 | $354K | |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 2,437 | 2,306 | $330K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.6% | 34,818 | 31,408 | $312K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.5% | 5,868 | 5,102 | $295K |
124 more codes
| 99285 | Emergency room visit (most serious) | 1.6% | 1,345 | $197K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 1,180 | $196K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 1,942 | $164K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.4% | 2,379 | $164K |
| 99284 | Emergency room visit (serious) | 1.3% | 1,541 | $160K |
| Z7502 | 1.3% | 4,241 | $151K | |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.0% | 665 | $124K |
| A4217 | Sterile water/saline, 500 ml | 1.0% | 9,053 | $120K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.0% | 1,584 | $120K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,856 | $118K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,294 | $115K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,141 | $85K |
| 84484 | <1% | 7,484 | $83K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,300 | $83K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,478 | $70K |
| 83690 | <1% | 7,255 | $58K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,606 | $56K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 640 | $55K |
| J3490 | Unclassified drugs | <1% | 34,211 | $48K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,324 | $41K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,134 | $31K |
| 96379 | <1% | 1,389 | $26K | |
| 81001 | <1% | 7,008 | $26K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 375 | $25K |
| 83605 | <1% | 2,368 | $25K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,260 | $24K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 966 | $24K |
| 0270 | <1% | 2,390 | $23K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,023 | $23K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,481 | $22K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 65 | $22K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 120 | $20K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,157 | $19K |
| 83880 | <1% | 674 | $17K | |
| 70496 | <1% | 102 | $17K | |
| 0360 | <1% | 203 | $17K | |
| 73630 | <1% | 418 | $15K | |
| 87040 | <1% | 1,012 | $15K | |
| 80306 | <1% | 493 | $14K | |
| 85379 | <1% | 1,352 | $14K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 123 | $13K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 526 | $13K |
| 81025 | <1% | 2,058 | $12K | |
| 70498 | <1% | 74 | $12K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 26 | $11K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 285 | $11K |
| 73610 | <1% | 332 | $11K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,179 | $11K |
| 73562 | <1% | 384 | $10K | |
| 72100 | <1% | 302 | $10K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,191 | $10K |
| 70486 | <1% | 55 | $10K | |
| Z7610 | <1% | 995 | $9K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,024 | $9K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,237 | $9K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 125 | $8K |
| 84703 | <1% | 1,202 | $8K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 158 | $8K |
| 99199 | Unlisted special service, procedure or report | <1% | 309 | $8K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 434 | $8K |
| 81003 | <1% | 3,065 | $7K | |
| 97139 | <1% | 246 | $7K | |
| 0710 | <1% | 157 | $7K | |
| 76830 | Ultrasound, transvaginal | <1% | 106 | $7K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 527 | $7K |
| 93971 | <1% | 68 | $6K | |
| 93970 | <1% | 38 | $6K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 150 | $6K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 605 | $5K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 672 | $5K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 810 | $4K |
| 87077 | <1% | 633 | $4K | |
| 82550 | <1% | 776 | $4K | |
| 85610 | <1% | 1,422 | $4K | |
| 73130 | <1% | 143 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 500 | $4K |
| 87186 | <1% | 512 | $4K | |
| 86140 | <1% | 833 | $4K | |
| 83735 | <1% | 840 | $4K | |
| 86900 | <1% | 432 | $4K | |
| 0259 | <1% | 1,183 | $4K | |
| 71020 | <1% | 124 | $4K | |
| 85730 | <1% | 770 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 576 | $3K |
| 87081 | <1% | 505 | $3K | |
| 93976 | <1% | 18 | $3K | |
| 73030 | <1% | 107 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 533 | $3K |
| 86901 | <1% | 414 | $2K | |
| 93975 | <1% | 13 | $2K | |
| 84702 | <1% | 171 | $2K | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | <1% | 46 | $2K |
| 71250 | <1% | 15 | $2K | |
| 0258 | <1% | 152 | $2K | |
| 86850 | <1% | 125 | $2K | |
| 29515 | <1% | 37 | $2K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 79 | $2K |
| 72040 | <1% | 56 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 110 | $1K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 83 | $1K |
| 73110 | <1% | 48 | $1K | |
| 94664 | <1% | 78 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 38 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 38 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 38 | $1K |
| 0272 | <1% | 1,023 | $1K | |
| 90715 | <1% | 28 | $1K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 122 | $1K |
| 85652 | <1% | 393 | $894.47 | |
| 87070 | <1% | 120 | $840.29 | |
| 84145 | <1% | 60 | $815.85 | |
| 29125 | <1% | 12 | $756.10 | |
| 87205 | <1% | 165 | $663.02 | |
| 87631 | <1% | 12 | $635.96 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 206 | $465.70 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 61 | $391.44 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 397 | $357.27 |
| 74018 | <1% | 25 | $330.07 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 28 | $294.88 |
| 82803 | <1% | 12 | $148.47 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 42 | $131.51 |
| 0250 | <1% | 53 | $36.85 | |
| 0370 | 0% | 28 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 43 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTANDE, BRETT (EVP/CFO)
| Provider | Location | Paid |
|---|---|---|
| Scripps Health | San Diego, CA | $64.23M |
| Scripps Health | La Jolla, CA | $9.79M |
| Scripps Health | La Jolla, CA | $502K |
| Scripps Health | La Jolla, CA | $57K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.